IRIDEX Corp (IRIX) stock
Close on Nov 17, 2026Market cap $12.29MP/E –Yield –
Earnings
Iridex's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Iridex's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 27, 2026 | Nov 11, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jul 4, 2026 | Aug 18, 2026after the close | $12.60M | -7.4% | -$0.07 | Release |
| Q1 FY2026ended Apr 4, 2026 | May 19, 2026after the close | $11.80M | -0.8% | -$0.03 | Release |
| Q4 FY2025ended Jan 3, 2026 | Mar 26, 2026after the close | $14.70M | +15.7% | -$0.01 | Release |
| Q3 FY2025ended Sep 27, 2025 | Nov 12, 2025after the close | $12.50M | +7.8% | -$0.09 | Release |
| Q2 FY2025ended Jun 28, 2025 | Aug 12, 2025after the close | $13.60M | +7.9% | -$0.06 | Release |
| Q1 FY2025ended Mar 29, 2025 | May 13, 2025after the close | $11.90M | +0.8% | -$0.10 | Release |
| Q4 FY2024ended Dec 28, 2024 | Mar 27, 2025after the close | $12.70M | – | -$0.05 | Release |
| Q3 FY2024ended Sep 28, 2024 | Nov 12, 2024after the close | $11.60M | -10.1% | – | Release |
| Q2 FY2024ended Jun 29, 2024 | Aug 8, 2024after the close | $12.60M | -2.3% | -$0.16 | Release |
| Q1 FY2024ended Mar 30, 2024 | May 14, 2024after the close | $11.80M | -13.9% | -$0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023after the close | $12.90M | -11.6% | -$0.11 | Release |
| Q2 FY2023ended Jul 1, 2023 | Aug 10, 2023after the close | $12.90M | -6.5% | -$0.17 | Release |
| Q1 FY2023ended Apr 1, 2023 | May 11, 2023after the close | $13.70M | +2.2% | -$0.13 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023after the close | $15.20M | -0.7% | -$0.07 | Release |
| Q3 FY2022ended Oct 1, 2022 | Nov 10, 2022after the close | $14.60M | +9.8% | -$0.11 | Release |
| Q2 FY2022ended Jul 2, 2022 | Aug 15, 2022after the close | $13.80M | – | -$0.14 | Release |
| Q1 FY2022ended Apr 2, 2022 | May 12, 2022after the close | $13.40M | – | -$0.15 | Release |
| Q4 FY2021ended Jan 1, 2022 | Mar 10, 2022after the close | $15.30M | – | -$0.15 | Release |
| Q3 FY2021ended Oct 2, 2021 | Nov 12, 2021before the open | $13.30M | – | -$0.14 | Release |
| Q2 FY2021ended Jul 3, 2021 | Aug 12, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Apr 3, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Jan 2, 2021 | Mar 22, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 26, 2020 | Nov 9, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 27, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
| Q1 FY2020ended Mar 28, 2020 | May 11, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Iridex's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| annual revenue | FY2026 | $51.00M – $53.00M | $51.00M – $53.00M | Reaffirmed | Aug 18, 2026 |
| growthnon-GAAP | FY2026 | +1% – +5% | – | New | Mar 26, 2026 |
| revenue | FY2026 | $51.00M – $53.00M | – | New | Mar 26, 2026 |
| adjusted operating expensesnon-GAAP | FY2026 | $19.00M – $19.50M | $19.00M – $19.50M | Reaffirmed | Aug 18, 2026 |
| adjusted operating expensesnon-GAAP | FY2026 | $19.00M – $19.50M | – | New | Mar 26, 2026 |
Guidance vs results
The last range Iridex gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q4 FY2021 | Revenue | $15.10M – $15.30M | $15.30M | Within range |
Guidance history
Every forecast Iridex put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 18, 2026 | adjusted operating expenses | FY2026 | $19.00M – $19.50M | Reaffirmed |
| Aug 18, 2026 | annual revenue | FY2026 | $51.00M – $53.00M | Reaffirmed |
| May 19, 2026 | adjusted operating expenses | FY2026 | $19.00M – $19.50M | New |
| May 19, 2026 | annual revenue | FY2026 | $51.00M – $53.00M | New |
| Mar 26, 2026 | adjusted operating expenses | FY2026 | $19.00M – $19.50M | New |
| Mar 26, 2026 | growth | FY2026 | +1% – +5% | New |
| Mar 26, 2026 | revenue | FY2026 | $51.00M – $53.00M | New |
| Aug 10, 2023 | Cyclo G6 probe sales | FY2023 | 61,000 – 63,000 | Raised |
| Aug 10, 2023 | Cyclo G6 systems installed base expansion | FY2023 | 210 – 230 | Lowered |
| Aug 10, 2023 | Total revenue | FY2023 | $55.00M – $57.00M | Lowered |
| May 11, 2023 | Cyclo G6 probe sales | FY2023 | 65,000 – 67,000 | Raised |
| May 11, 2023 | Cyclo G6 systems installed base | FY2023 | 225 – 250 | Lowered |
| May 11, 2023 | Total revenue | FY2023 | $57.00M – $59.00M | Reaffirmed |
| Mar 9, 2023 | Cyclo G6 probe sales | FY2023 | 65,000 – 67,000 | New |
| Mar 9, 2023 | Cyclo G6 systems installed base | FY2023 | 225 – 250 | Lowered |
| Mar 9, 2023 | Total revenue | FY2023 | $57.00M – $59.00M | New |
| Nov 10, 2022 | Glaucoma Laser System installed base to expand | FY2022 | 225 – 250 | Reaffirmed |
| Nov 10, 2022 | Cyclo G6 probe unit sales | FY2022 | 60,000 | Raised |
| Nov 10, 2022 | total revenue | FY2022 | $56.00M – $58.00M | Reaffirmed |
| Aug 15, 2022 | Cyclo G6 probe sales | FY2022 | 61,000 – 63,000 | Raised |
| Aug 15, 2022 | Glaucoma Laser System installed base | FY2022 | 225 – 250 | Lowered |
| Aug 15, 2022 | total revenue | FY2022 | $56.00M – $58.00M | Lowered |
| May 12, 2022 | Cyclo G6 probe sales | FY2022 | 67,000 – 70,000 | Raised |
| May 12, 2022 | Cyclo G6 systems installed base to expand | FY2022 | 225 – 250 | Lowered |
| May 12, 2022 | Total revenue | FY2022 | $57.00M – $59.00M | Reaffirmed |
| Mar 10, 2022 | Cyclo G6 probe sales | FY2022 | 67,000 – 70,000 | New |
| Mar 10, 2022 | Cyclo G6 systems installed base to expand | FY2022 | 225 – 250 | Lowered |
| Mar 10, 2022 | Cyclo G6 probe sales growth | FY2022 | +15% – +20% | New |
| Mar 10, 2022 | Total revenue | FY2022 | $57.00M – $59.00M | New |
| Jan 11, 2022 | Total revenue | Q4 FY2021 | $15.10M – $15.30M | New |
| Jan 11, 2022 | Total revenue | FY2021 | $53.70M – $53.90M | Raised |
| Nov 12, 2021 | Glaucoma Laser System sales | FY2021 | 210 – 225 | New |
| Nov 12, 2021 | Cyclo G6 probe sales | FY2021 | 58,000 – 60,000 | Raised |
| Nov 12, 2021 | total revenue | FY2021 | $52.00M – $53.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Iridex filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025Results
- Update
- Results
- News
- Results
- Results
- Results
- Results
- News
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024Results
See a number that looks wrong?